Introduction
The possibility that local mechanisms in the respiratory tract might play a significant role in the prevention of influenza was first suggested by Francis (1940) . Ten 
years later Fazekas de St Groth
& Donnelly (1950) demonstrated that in mice, protection against influenza correlated better with local than with serum antibodies and that these secretory antibodies could be efficiently stimulated by local application of the antigen.
It would, therefore, seem a logical approach to induce immunity against influenza in man by the respiratory route. Przesmycki, Sawicki & Dobrowolska (1959) reported favourable results from a series of field studies involving several thousands of subjects with intranasally administered polyvalent inactivated influenza virus vaccines. However, it was not until Tomasi et al. (1965) showed that the * Clinical Research Department t Department of Human Vaccines $ Statistical Department secretory antibodies belong to a different class of immunoglobulins (IgA), before interest in practical application of local stimulation of secretory antibodies was revived.
Waldman et al. (1968) and Kasel et al. (1969) demonstrated that direct application to the upper respiratory tract of inactivated influenza virus vaccine resulted in production of local IgA virus neutralizing antibodies. Encouraged by these results, the first field studies with killed influenza virus vaccine given by inhalation were executed in 1967-68 by Waldman, Mann & Small (1969) . The protective efficacy of intranasal vaccination with killed influenza virus vaccine found in these studies was further confirmed by successive double blind studies by and by Waldman & Coggins (1972 (Fig. 1) . One dose of the vaccine corresponded to four puffs. The vaccine was administered during deep inhalation, either given as one puff in each nostril (Fig. 2) and two in the oropharynx ('2 x nose -2 x mouth') or as two puffs in each nostril ('4 x nose').
Stability tests showed that at room temperature the antigenicity of the vaccine was well preserved for at least 18 months.
All studies were placebo-controlled and, with the exception of the Reading study where variable doses and different routes of administration were tested, double blind. Allocation to the active vaccine or the placebo aerosol was done according to a predetermined randomization scheme. A summary of the trials is given in Table 1 .
The Reading trial was primarily set up as a tolerance study and as an investigation into the immunologic response. In the South African trials (5a-d) a group consisting of an equal number of subjects were included who received parenteral vaccine. Half of the subjects of the groups who received the vaccine were given a booster immunization 4 weeks after the first one; the remaining subjects received placebo spray at the same time.
The systemic antibody responses were studied from serum samples taken from all volunteers (Reading) or from each fortieth subject (South African trials). Specific antibodies against the A2 Hong Kong strain were determined as haemagglu- tination-inhibition antibodies in sera taken before and 4 weeks after vaccination. In the Reading experiment the postvaccination samples were taken 6 and 10 weeks after immunization. In the Naples study nasal washes were taken from each twentieth subject before and 4 weeks after vaccination.
Local antibodies were determined as specific neutralizing antibody titres found in the nasal wash samples.
All cases of acute respiratory disease which occurred among the studied population between the day of vaccination and the end of the influenza epidemic season were recorded. Blood samples were taken from them at the onset of the disease and 3 weeks thereafter.
Attack rates were exclusively based on the serologically confirmed cases of influenza, i.e. four-fold rise in CF and/or HI titres between first day sera and convalescence sera taken 3 weeks after the onset of the illness.
Except in the Reading andZagrebstudieswhere this was not feasible, serological confirmation of influenza was based on four-fold increase in CF titres between prevaccination and postepidemic sera. In most of the Reading sera the CF titres could not be determined due to anticomplement activity; therefore, the agar gel precipitation test (AGP test) has been used instead (Beard, 1970) .
Two additional field studies were executed in the United Kingdom under the auspices of Riker Laboratories among factory workers of British Leyland and Unilever Ltd. In these studies spray vaccine (Table 2) .
The local antibody response studied from nasal washes taken before and after vaccination showed a slight increase in titres after intranasal vaccination (Table 3) .
Protective effect
The attack-rates for influenza among our study population were very low. In the season 1969/70 a fairly high attack rate of A2 Hong Kong influenza was reported in most Western European countries. The epidemic, however, started at an unexpectedly early date (first week of December) and therefore, the vaccination procedure was started too late in both the Naples and Zagreb trials. In Zagreb the epidemic outbreak coincided with the start of our vaccination programme. In Naples the epidemic reached its peak when we started the immunization. Nevertheless, we have attempted to assess the protective effect of the vaccination by disregarding the cases of influenza illness which occurred in the first 2 weeks following vaccination. In 1970 a fairly high attack rate of A2 Hong Kong influenza was also reported in South Africa. However, in our studies the incidence of influenza illness was disappointingly low. The studies were carried out in rather isolated communities and the low attack-rate could be due to a 'herd immunity' induced by the high vaccination rate as a result of our immunization schedule. Table 4 shows the combined figures on the incidence of serologically con- Fig. 3 . Protection-rate was calculated from the numbers of serologically confirmed influenza cases among the studied population and expressed as the percentage reduction in the influenza incidence among the vaccinees as conmpared with the placebo group.
Due to the low incidence of influenza, the difference between the attack-rates among the vaccinated groups and placebo controls for each individual trial was not statistically significant. However, the same positive trend towards protection from the vaccine was repeatedly found. A weighted average of the protection-rates derived from the reported percentages of infection in the various trials was calculated and was found to be 580/0 (statistical significance P -0 04).
If the results of the Naples and Zagreb trials were excluded because the immunization was given when the epidemic had already started, the average protection rate was found to be 69% (P=0 02). If one would exclude the Reading and Zagreb trials because the trial set up for these two studies was somewhat different from that in the others, the average of protection-rates was even found to be 740 (P-0-02) (see Table 5 ). The general acceptance of the vaccination by spray by the subjects who participated in the trials was extremely favourable. Particularly the intranasal route was very well accepted.
Discussion
Our results on the immunologic response after intranasal vaccination are in agreement with those reported by previous investigators (Waldman et al., 1968) . The seroconversion rate after spray vaccine was very low. Nasal antibody response was found to be more marked and consistent. The determination of the local antibodies was done in the unconcentrated nasal wash samples; for this reason we must have missed some of the smaller responses. In a later investigation, where local antibody responses after nasal spray and subcutaneous vaccine were compared, we used concentrated nasal washings. With the increased sensitivity of secretory antibody determination, a higher response was found (to be published later).
The combined results of the double blind trials present statistically significant evidence for the protective effect of the vaccine given by inhalation. Two other field studies reported in this paper give further support to our conclusion that the protection after intranasal spray vaccine seems comparable with that attained after parenteral vaccine.
Conclusion
The intranasal vaccination with killed influenza virus vaccine seems an acceptable alternative route of immunization against influenza. The protective effect is found to be comparable with that attained after parenteral vaccine. The intranasal route gives negligible side-effects. This lack of systemic or local reaction to the intranasal vaccine may enhance its acceptance by the public.
